Prof. Peter Lawætz Andersen

Professor Peter Andersen

PeterAndersonVaccine Research and Development at Statens Serum Institut, Copenhagen, Denmark

Visiting Schedule
Sydney, February 24th
Dunedin, February 27th
Palmerston North, March 4th

Hosted by Joanna Kirman, University of Otago

 

 

Prof. Peter Lawætz Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut . Prior to this he was director of Infectious Disease Immunology (1997-2002) and the Tuberculosis Research Unit (1991-1997) both at SSI. Prof. Andersen has since 2006 been Honorary Professor at Copenhagen University. In his current position at the SSI, he is responsible for the overall coordination of vaccine research and development, covering activities from early research and to clinical development. Prof. Andersens research has been focused on the identification and characterisation of antigens, immune mechanisms and vaccine delivery systems that mediate protection against various pathogens and his main scientific interest has been immunity to intracellular pathogens such as Mycobacterium tuberculosis and Clamydia trachomatis. Prof. Andersen has pioneered work both on novel diagnostic assays (the IGRA assays), novel TB vaccines (H1/H4/H56) and the CAF series of liposomal adjuvants. Prof. Andersen is the coordinator of several multidisciplinary research consortia including the international Center for Nano-Vaccines and the Gates Grand Challenge 12 Consortium. He has served on a number of committees to advise and co-ordinate strategies for vaccine and diagnostic development and has organized and chaired numerous international meetings. Prof. Andersen has >250 publications, within the field of infection, immunity and vaccine research in peer-reviewed journals and is the inventor of >20 novel patents within the vaccine field.

 

Selected Recent Publications

Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Bigbee M, Milk L, Gideon HP, Rodgers M, Cochran C, Guinn KM, Sherman DR, Klein E, Janssen C, Flynn JL, Andersen P. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest. 2012 Jan 3;122(1):303-14.

Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011 Feb;17(2):189-94.

Olsen AW, Theisen M, Christensen D, Follmann F, Andersen P. Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One. 2010 May 21;5(5):e10768.

Aagaard CS, Hoang TT, Vingsbo-Lundberg C, Dietrich J, Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol. 2009 Aug 15;183(4):2659-68.

Hoang TT, Nansen A, Roy S, Billeskov R, Aagaard C, Elvang T, Dietrich J, Andersen P.?Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. PLoS One. 2009 Jun 16;4(6):e5928.

Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands I, Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol. 2009 Jun 15;182(12):8047-55.

Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol. 2009 May-Jun;87(4):279-86.

Andersen CS, Agger EM, Rosenkrands I, Gomes JM, Bhowruth V, Gibson KJ, Petersen RV, Minnikin DE, Besra GS, Andersen P. A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. J Immunol. 2009 Jan 1;182(1):424-32.

Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis. 2008 Sep 1;198(5):758-67.

Andersen P. Tuberculosis vaccines - an update. Nat Rev Microbiol. 2007 Jul;5(7):484-7.